Home › Therapeutic areas › Oncology › Multiple Myeloma

Multiple Myeloma (12 companies)

Companies with an active program in Multiple Myeloma.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 $256M 10
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
CCCC C4 Therapeutics Oncology 1 Phase 2 $332M 2
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 $187M 4
CLRB Cellectar Biosciences Oncology 1 Phase 2 $9.2M 7
FATE Fate Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $124M 10
FHTX Foghorn Therapeutics Oncology 1 Preclinical $110M 4
LEGN Legend Biotech Oncology Rare 5 Approved $3.12B 17
ORIC Oric Pharmaceuticals Oncology 1 Phase 3 $831M 5
SANA Sana Biotechnology MetabolicOncology 1 Phase 1 $563M 4
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 $3.90B 9
TLX Telix Pharmaceuticals Oncology 1 Approved $3.01B 25